Experienced in Rhizomelic Pseudopolyarthritis

Dr. Eric A. Peters

Rheumatology
Arizona Arthritis And Rheumatology Associates P C
10615 W Thunderbird Blvd, Suite B100, 
Sun City, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Rhizomelic Pseudopolyarthritis
Arizona Arthritis And Rheumatology Associates P C
10615 W Thunderbird Blvd, Suite B100, 
Sun City, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Peters is a Rheumatologist in Sun City, Arizona. Dr. Peters is rated as an Experienced provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Palindromic Rheumatism, Postmenopausal Osteoporosis, and Osteoporosis. Dr. Peters is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES P C
10615 W Thunderbird Blvd, Suite B100, Sun City, AZ 85351
Other Locations
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES P C
1958 Commerce Ctr Cir, Prescott, AZ 86301
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES P C
4550 E Bell Rd, Phoenix, AZ 85032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Combination product
Study Drugs: Abaloparatide solid microstructured transdermal system, Abaloparatide subcutaneous
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

2 Total Publications

Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis".
Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis".
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: September 07, 2023
Similar Doctors
Distinguished in Rhizomelic Pseudopolyarthritis
Dr. Alexander C. Hu
Rheumatology
Distinguished in Rhizomelic Pseudopolyarthritis
Dr. Alexander C. Hu
Rheumatology

Arizona Arthritis And Rheumatology Associates P C

4550 E Bell Rd, Suite 170, 
Phoenix, AZ 
 (17.7 miles away)
480-443-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Hu is a Rheumatologist in Phoenix, Arizona. Dr. Hu is rated as a Distinguished provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Rhizomelic Pseudopolyarthritis, Gout, and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. Dr. Hu is currently accepting new patients.

Distinguished in Rhizomelic Pseudopolyarthritis
Dr. Vijayabhanu Mahadevan
Rheumatology
Distinguished in Rhizomelic Pseudopolyarthritis
Dr. Vijayabhanu Mahadevan
Rheumatology

American Arthritis And Rheumatology Associates - Az PLLC

12665 W Smokey Dr, Suite 140, 
Surprise, AZ 
 (3.4 miles away)
623-219-4040
Languages Spoken:
English, Hindi, Tamil
See accepted insurances
Offers Telehealth

Vijayabhanu Mahadevan is a Rheumatologist in Surprise, Arizona. Dr. Mahadevan is rated as a Distinguished provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. Her top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Rhizomelic Pseudopolyarthritis.

Distinguished in Rhizomelic Pseudopolyarthritis
Dr. Rajat K. Dhar
Rheumatology
Distinguished in Rhizomelic Pseudopolyarthritis
Dr. Rajat K. Dhar
Rheumatology

Arizona Arthritis And Rheumatology Associates P C

10615 W Thunderbird Blvd, Suite B100, 
Sun City, AZ 
 (0.1 miles away)
480-443-8400
Languages Spoken:
English, Bengali
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajat Dhar is a Rheumatologist in Sun City, Arizona. Dr. Dhar is rated as a Distinguished provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, and Osteoporosis. Dr. Dhar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Peters's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile